Overview Biotech companies are attracted to licensing deals for a variety of important reasons: 1) to provide an alternative source of capital from the licensee to fund R&D and commercial operations including, but not limited to, advancement of the asset(s) in...
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q2 2019 Report: Global Trends in Biopharma Transactions applies the latest data to analyze current activities in the life science deal...
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q2 2019 Report: Global Trends in Medtech Transactions applies the latest data to analyze current activities in the life sciences deal...
BOSTON, June 19, 2019 — Locust Walk, a global life science transaction firm, today announced the appointments of Neil Higgins, Managing Director of Financing, and Turner Grant, Senior Vice President of Financing. Both executives will report to Brian Coleman,...
The Crush Life Sciences Board Meeting series is designed to open minds and explore new trends that will translate into more effective governance and success throughout the life science industry. The Board Meeting is an exclusive, invite-only, off the record meeting...
